Business Context and Reporting Period
This Form 8-K is filed by Bellevue Life Sciences Acquisition Corp. (BLAC) on December 17, 2024, reporting events occurring on December 17 and December 20, 2024. BLAC is a Delaware corporation and an emerging growth company engaged in a proposed business combination with OSR Holdings Co., Ltd. (OSR Holdings), a Korean corporation. The filing details amendments to key transaction agreements regarding the merger and a private investment in public equity (PIPE) transaction.
Key Financial Metrics
This filing is a current report regarding material definitive agreements and does not contain audited financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period. The only specific financial figure disclosed relates to the PIPE Investment:
- PIPE Investment Amount: $20,000,000 aggregate purchase price.
- Shares Issued: 222,222 shares of Series A Preferred Stock.
- Price Per Share: $90.00.
The filing text does not provide a clear value for BLAC's or OSR Holdings' current revenue, debt, or cash position.
Material Changes and Agreements
Two material amendments were executed to facilitate the proposed business combination:
- First Amendment to PIPE Subscription Agreement (Dec 17, 2024): BLAC and Toonon Partners Co., Ltd. amended their October 2024 agreement to remove the redemption features of the Series A Preferred Stock. This change affects the Certificate of Designations to be filed with the Delaware Secretary of State upon closing.
- First Amendment to Amended and Restated Business Combination Agreement (Dec 20, 2024): BLAC and OSR Holdings amended the May 2024 agreement to modify Exhibit B (Form of Non-Participating Stockholder Joinder). The amendment adds a specific termination date for the put right and call right set forth in the joinder.
Outlook, Risks, and Management Commentary
Management Commentary and Conflicts: Kuk Hyoun Hwang serves as CEO of BLAC and Chairman of OSR Holdings, creating potential conflicts of interest. An independent M&A Committee was formed to review and unanimously approve the agreements. Stockholders are urged to read the preliminary and definitive proxy statements for detailed information.
Risks and Contingencies: The filing includes extensive forward-looking statements subject to significant risks, including:
- Failure to obtain stockholder approval or satisfy closing conditions.
- Termination of the definitive agreement due to legal proceedings or unsolicited offers.
- Inability to list the surviving company's stock on Nasdaq.
- Disruption of OSR Holdings' operations and inability to retain key employees.
- Impact of global health disruptions (e.g., COVID-19) and changes in laws or regulations.
Guidance: No specific financial guidance or earnings outlook is provided in this document.
Investor Verification Checklist
- Verify the terms of the removed redemption features in the Series A Preferred Stock Certificate of Designations.
- Confirm the specific termination date added to the put and call rights for Non-Participating Stockholders.
- Review the definitive proxy statement (Form S-4) for details on the business combination valuation and voting procedures.
- Assess the conflict of interest disclosures regarding Kuk Hyoun Hwang's dual roles.
- Monitor the status of the Form S-4 registration statement and the scheduled special meeting of stockholders.